REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-U.S. dollar slides as stocks rally; focus on Fed

Mon, 14th Sep 2020 20:41

* Suga set to succeed Abe as Japan PM, focus turns to new cabinet
* Dollar falls to two-week low vs yen
* Dollar under pressure ahead of Fed policy meeting outcome on Wed
* Fed expected to reinforce near-zero rates until 2023
* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

(Adds new comment, updates prices)
By Gertrude Chavez-Dreyfuss
NEW YORK, Sept 14 (Reuters) - The dollar slipped on Monday against its major peers, dropping to a
two-week low versus the yen, as positive news about a COVID-19 vaccine and a wave of merger and
acquisition deals lifted the mood in global equity markets.
Investors also looked ahead to an event-packed week which includes a Federal Reserve meeting and the
appointment of a new Japanese premier.
U.S. stocks rose on Monday on signs of progress in developing a COVID-19 vaccine and a flurry of
multibillion-dollar deals, including reports of Oracle winning the battle for the U.S. arm of
TikTok.
Drugmaker AstraZeneca on Monday said it resumed its British clinical trials of its COVID-19
vaccine, one of the most advanced in development, helping kick off a rally in stocks.
"There's some positive traction on the coronavirus vaccine and that has helped lift the market," said
Amo Sahota, executive director at currency advisory firm Klarity FX in San Francisco.
"Generally I would call it a soft, upbeat day. I don't know if we have learned anything significantly
new today that would give us any indication about trend building. Today it's a day that's more supportive
of equities, and so the dollar weakens off," he added.
In afternoon trading, the dollar index fell 0.3% to 93.029, after posting two straight weeks of
gains.
Speculators trimmed net short dollar positions for the second straight week to $32.67 billion,
according to Reuters calculations and Commodity Futures Trading Commission data. That's off nine-year
highs of $33.68 billion in late August.
This week's Fed Reserve meeting will be its first since Chairman Jerome Powell unveiled a policy shift
toward greater tolerance of inflation, effectively pledging to keep interest rates low for longer.
"The updated 'dot-plot' is expected to reinforce the message that the current zero-interest-rate
policy stance is appropriate through 2023," said NatWest in its latest research note, a scenario that is
negative for the dollar.
Fed officials' median projection on the number of rate moves is commonly referred to as its
"dot-plot."
The dollar fell 0.4% against the yen to 105.70 yen, after earlier sliding to a two-week low.
The Bank of Japan's meeting on Thursday is not expected to yield any policy changes but the bank may
be quizzed on whether it could follow the Fed's inflation stance.
On the political front, Chief Cabinet Secretary Yoshihide Suga was picked to head Japan's ruling party
on Monday, meaning on Wednesday in parliament he is set to be selected by his peers as prime minister,
taking over from Shinzo Abe.
Suga has vowed to continue Abe's policies.
The euro was up 0.2% versus the dollar at $1.1867.
The single currency had spiked to a one-week high above $1.191 after Thursday's European Central Bank
meeting, before easing back as policymakers talked it down the next day.

Currency bid prices at 3:36 PM (1936 GMT)
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar EUR= $1.1866 $1.1845 +0.18% +5.85% +1.1887 +1.1831
Dollar/Yen JPY= 105.6900 106.1400 -0.42% -2.91% +106.1900 +105.5600
Euro/Yen EURJPY= 125.42 125.75 -0.26% +2.85% +125.9000 +125.2900
Dollar/Swiss CHF= 0.9080 0.9086 -0.07% -6.18% +0.9098 +0.9060
Sterling/Dollar GBP= 1.2862 1.2793 +0.54% -2.99% +1.2918 +1.2778
Dollar/Canadian CAD= 1.3175 1.3174 +0.01% +1.46% +1.3196 +1.3154
Australian/Doll AUD= 0.7294 0.7283 +0.15% +3.89% +0.7303 +0.7265
ar
Euro/Swiss EURCHF= 1.0775 1.0764 +0.10% -0.71% +1.0776 +1.0758
Euro/Sterling EURGBP= 0.9224 0.9254 -0.32% +9.11% +0.9263 +0.9202
NZ NZD= 0.6705 0.6664 +0.62% -0.46% +0.6717 +0.6660
Dollar/Dollar
Dollar/Norway NOK= 9.0281 9.0336 -0.06% +2.84% +9.0531 +8.9861
Euro/Norway EURNOK= 10.7140 10.7024 +0.11% +8.91% +10.7269 +10.6716
Dollar/Sweden SEK= 8.7631 8.7687 +0.08% -6.25% +8.7881 +8.7539
Euro/Sweden EURSEK= 10.4001 10.3916 +0.08% -0.66% +10.4220 +10.3756


(Reporting by Gertrude Chavez-Dreyfuss; editing by Jonathan Oatis)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.